文献速递皮肤肿瘤

抑制p38/MK2信号通路可防止黑色素瘤血管侵犯

Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma.
PubMed 文献 · J Invest Dermatol · 2019-10-14

该研究通过对22例患者来源的黑色素瘤细胞系进行基因表达谱分析,发现CDH1阴性是侵袭性表型的替代标志物,p38/MK2通路可调控CDH1表达并控制黑色素瘤进展。机制上,抑制MK2可防止黑色素瘤诱导的血管屏障破坏、降低PODXL和DEL-1表达,并在体内阻止血管播散;PODXL和DEL-1高表达与患者生存期差相关,可作为预后标志物。

要点

  • CDH1阴性可作为黑色素瘤侵袭性表型的替代标志物。
  • p38/MK2通路通过调控CDH1表达控制黑色素瘤进展。
  • 抑制MK2可防止血管屏障破坏和体内血管播散,PODXL和DEL-1或为预后标志物。

核心结论

  • p38/MK2信号通路调控黑色素瘤侵袭性表型,抑制MK2可防止血管侵犯和播散。

研究设计与样本

  • 对22例患者来源的黑色素瘤细胞系进行基因表达谱分析,并在体内验证MK2抑制的效果。

主要发现

  • CDH1阴性是侵袭性表型的替代标志物,CDH1表达可通过调节p38或MK2活性开启或关闭。
  • 抑制MK2可防止黑色素瘤诱导的血管屏障破坏,降低PODXL和DEL-1表达,并在体内阻止血管播散。
  • PODXL和DEL-1在黑色素瘤患者中的表达与生存期差相关,可作为预后标志物。

关键数值与推荐

  • CDH1阴性作为侵袭性表型的替代标志物。
  • PODXL和DEL-1表达与黑色素瘤患者生存期差相关,可作为预后标志物。

临床怎么用

  • MK2下游靶点可作为候选治疗靶点,PODXL和DEL-1可用于预后评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Melanoma cells can switch between distinct gene expression profiles, resulting in proliferative or invasive phenotypes. Signaling pathways involved in this switch were analyzed by gene expression profiling of a cohort of 22 patient-derived melanoma cell lines. CDH1 negativity was identified as a surrogate marker for the invasive phenotype. CDH1 expression could be turned on and off by modulating activity of p38 or its downstream target MK2, suggesting that this pathway controls melanoma progression. Mechanistically, MK2 inhibition prevented melanoma-induced vascular barrier disruption, reduced the expression of PODXL and DEL-1, and prevented vascular dissemination in vivo. PODXL and DEL-1 expression in patients with melanoma were associated with poor survival and thus can be used as prognostic markers. Downstream targets of MK2 may thus serve as candidate therapeutics.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Wenzina J, Holzner S, Puujalka E, et al. Inhibition of p38/MK2 Signaling Prevents Vascular Invasion of Melanoma. J Invest Dermatol. 2019. PMID: 31622599. doi:10.1016/j.jid.2019.08.451

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。